Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human TNF-alpha Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 210TA02M/CF
This item is not returnable.
View return policy
Description
Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 221. The ED50 for this effect is 25-100 pg/mL. The specific activity of Recombinant Human TNF-alpha is approximately 7.6 x 104 IU/μg, which is calibrated against human TNF-alpha WHO International Standard (NIBSC code: 88/786). Specific activity is for reference purposes only and is not routinely tested.Specifications
Lyophilized from a 0.2μm filtered solution in PBS. | |
17.5 kDa | |
2mg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
APC1 protein, Cachectin, Cachetin, DIF, TNF, TNF, monocyte-derived, TNF-a, TNFA, TNFalpha, TNF-alphacachectin, TNFATNF, macrophage-derived, TNFG1F, TNFSF1A, TNFSF2, TNFSF2TNF superfamily, member 2, tumor necrosis factor, tumor necrosis factor (TNF superfamily, member 2), tumor necrosis factor alpha, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha | |
Recombinant |
7124 | |
TNF-alpha | |
E. coli-derived human TNF-alpha protein Val77-Leu233, with and without an N-terminal Met | |
Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 221. The ED50 for this effect is 25-100 pg/mL. | |
Unconjugated | |
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction